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Abstract
Background: Most publications about selective reporting in clinical trials have focussed on outcomes. However, selective
reporting of analyses for a given outcome may also affect the validity of findings. If analyses are selected on the basis of the
results, reporting bias may occur. The aims of this study were to review and summarise the evidence from empirical cohort
studies that assessed discrepant or selective reporting of analyses in randomised controlled trials (RCTs).
Methods and Findings: A systematic review was conducted and included cohort studies that assessed any aspect of the
reporting of analyses of RCTs by comparing different trial documents, e.g., protocol compared to trial report, or different
sections within a trial publication. The Cochrane Methodology Register, Medline (Ovid), PsycInfo (Ovid), and PubMed were
searched on 5 February 2014. Two authors independently selected studies, performed data extraction, and assessed the
methodological quality of the eligible studies. Twenty-two studies (containing 3,140 RCTs) published between 2000 and
2013 were included. Twenty-two studies reported on discrepancies between information given in different sources.
Discrepancies were found in statistical analyses (eight studies), composite outcomes (one study), the handling of missing
data (three studies), unadjusted versus adjusted analyses (three studies), handling of continuous data (three studies), and
subgroup analyses (12 studies). Discrepancy rates varied, ranging from 7% (3/42) to 88% (7/8) in statistical analyses, 46%
(36/79) to 82% (23/28) in adjusted versus unadjusted analyses, and 61% (11/18) to 100% (25/25) in subgroup analyses. This
review is limited in that none of the included studies investigated the evidence for bias resulting from selective reporting of
analyses. It was not possible to combine studies to provide overall summary estimates, and so the results of studies are
discussed narratively.
Conclusions: Discrepancies in analyses between publications and other study documentation were common, but reasons
for these discrepancies were not discussed in the trial reports. To ensure transparency, protocols and statistical analysis
plans need to be published, and investigators should adhere to these or explain discrepancies.
Please see later in the article for the Editors’ Summary.
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Introduction
Selective reporting in clinical trial reports has been described
mainly with respect to the reporting of a subset of the originally
recorded outcome variables in the final trial report. Selective
outcome reporting can create outcome reporting bias, if reporting is
driven by the statistical significance or direction of the estimated
effect (e.g., outcomes where the results are not statistically significant
are suppressed or reported only as p.0.05) [1]. A recent review
showed that statistically significant outcomes were more likely to be
fully reported than non-significant outcomes (range of odds ratios:
2.2 to 4.7). In 40% to 62% of studies at least one primary outcome
was changed, introduced, or omitted between the protocol and the
trial publication [2]. Another review reached similar conclusions
and also found that studies with significant results tended to be
published earlier than studies with non-significant results [3].
Other types of selective reporting may also affect the validity of
reported findings from clinical trials. Discrepancies can occur in
analyses, if data for a given outcome are analysed and reported
differently from the trial protocol or statistical analysis plan. For
example, a trial’s publication may report a per protocol analysis
rather than a pre-planned intention-to-treat analysis, or report on
an unadjusted analysis rather than a pre-specified adjusted
analysis. In the latter example, discrepancies in analyses may also
occur if adjustment covariates are used that are different to those
originally planned. If analyses are selected for inclusion in a trial
report based on the results being more favourable than those
obtained by following the analysis plan, then analysis reporting
bias occurs in a similar way to outcome reporting bias.
Examples of the various ways in which selective reporting can occur
in randomised controlled trials (RCTs) have previously been described
[4]. Furthermore, a systematic review of cohorts of RCTs comparing
protocols or trial registry entries with corresponding publications
found that discrepancies in methodological details, outcomes, and
analyses were common [5]. However, no study to our knowledge has
yet systematically reviewed the empirical evidence for the selective
reporting of analyses in clinical trials or examined discrepancies with
documents apart from the protocol or trial registry entry.
This study aimed to fill this gap by reviewing and summarising
the evidence from empirical cohort studies that have assessed (1)
selective reporting of analyses in RCTs and (2) discrepancies in
analyses of RCTs between different sources (i.e., grant proposal,
protocol, trial registry entry, information submitted to regulatory
authorities, and the publication of the trial’s findings), or between
sections within a publication.
Methods
Study Inclusion Criteria
We included research that compared different sources of
information when assessing any aspect of the analysis of outcome
data in RCTs.
Cohorts containing RCTs alone, or a mixture of RCTs and non-
RCTs were eligible. For those cohorts where it was not possible to
identify the study type (i.e., to determine whether any RCTs were
included), we sought clarification from the authors of the cohort
study. Studies were excluded where inclusion of RCTs could not be
confirmed, or where only non-RCTs had been included.
Figure 1. PRISMA flow diagram.
doi:10.1371/journal.pmed.1001666.g001
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Search Strategy
The search was conducted without language restrictions. In
May 2013, the Cochrane Methodology Register, Medline
(Ovid), PsycInfo (Ovid), and PubMed were searched (Text S2).
These searches were updated on 5 February 2014, except for
the search of the Cochrane Methodology Register, which has
been unchanged since July 2012. Cochrane Colloquium
conference proceedings from 2011, 2012, and 2013 were
hand-searched, noting that abstracts from previous Cochrane
Colloquia had already been included in the Cochrane
Methodology Register. A citation search of a key article [1]
was also performed. The lead or contact authors of all
identified studies and other experts in this area were asked to
identify further studies.
Two authors independently applied the inclusion criteria to the
studies identified. Any discrepancies between the authors were
resolved through discussion, until consensus was reached.
Data Extraction
One author extracted details of the characteristics and results
of the empirical cohort studies. Information on the main
objectives of each empirical study was also extracted, and the
studies were separated according to whether they related to
selective reporting or discrepancies between sources. Selective
reporting of analyses was defined as when the reported analyses
had been selected from multiple analyses of the same data for a
given outcome. A discrepancy was defined as when information
was absent in one source but reported in another, or when the
information given in two sources was contradictory. If selective
reporting bias was studied, the definition of ‘‘significance’’ used
in each cohort was noted (i.e., direction of results or whether the
study used a particular p-value [e.g., p,0.05] to determine
significance).
Data extraction was checked by another author. No masking
was used, and disagreements were resolved through discussion.
Methodological Quality
In the absence of a recognised tool to evaluate the methodo-
logical quality of the empirical studies eligible for this review, we
developed and used three criteria to assess methodological quality:
1. Independent data extraction by at least two people
High quality: data extraction completed independent-
ly by at least two people.
Methodological concerns: data extraction not
completed independently by at least two people.
Uncertain quality: not stated.
2. Definition of positive and negative findings
High quality: clearly defined.
Methodological concerns: not clearly defined.
Not applicable: this was not included in the objectives
of the study.
3. Risk of selective reporting bias in the empirical study
High quality: all comparisons and outcomes men-
tioned in the methods section of the empirical study
report are fully reported in the results section of the
publication.
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Methodological concerns: not all comparisons and
outcomes mentioned in the methods section of the
empirical study report are fully reported in the results
section of the publication.
Two authors independently assessed these items for all studies. An
independent assessor (Matthew Page) was invited to assess one study
[6] because the first author was directly involved in its design. Any
discrepancies were resolved through a consensus discussion with a third
reviewer not involved with the included studies.
Data Analysis
This review provides a descriptive summary of the included
empirical cohort studies. We refrained from any statistical
combination of the results from the different cohorts because of
the differences in their design.
Table 5. Statistical analyses.
Study (Maximum Number of
RCTs) Qualitya Results Percent of RCTs (Number)
Chan, 2008 [15] (n=70) H–H Trial design: discrepancy (contradiction) between protocol and
publication (equivalence trial reported as a superiority trial)
1% (1/70)
Statistical test used for primary outcome: discrepancy
(contradiction) between protocol and publication (statistical
methods for analysing the primary outcomes were described
in 39 protocols)
64% (25/39)
Statistical test used for primary outcome: discrepancy
(information absent) between protocol and publication
(statistical methods for analysing the primary outcomes
were described in 42 publications)
7% (3/42)
Interim analyses: discrepancy (information absent) between
protocol and publication (reported in protocol but not in
publication) (interim analyses were described in 13 protocols)
62% (8/13)
Interim analyses: discrepancy (contradiction) between
publication and protocol (reported in publication but it
was explicitly stated in the protocol that there would be none)
(interim analyses were reported in seven publications)
29% (2/7)
Hahn, 2002 [17] (n=15) X–H Analysis plan: discrepancy (contradiction) between protocol
and publication (statistical analysis plan was described in only
eight protocols)
88% (7/8)
Turner, 2008 [27] (n=74) HHH Methods: discrepancy (contradiction) between FDA review
and publication (only 51 of the 74 FDA-registered studies
were published)
22% (11/51)
Statistical tests: discrepancy (contradiction) between FDA
review and publication
16% (4/51)
Melander, 2003 [20] (n=42) ?HH ITT/PP analysis: one analysis included in publication
(usually favouring PP) (only 25 of the 42 studies were
submitted studies with stand-alone publications)
92% (23/25)
Vedula, 2013 [28] (n=11) HHH Definition of ITT: discrepancy (contradiction) between
the protocol and publication (ITT definition described in
both protocol and publication for three trials)
67% (2/3)
Rising, 2008 [23] (n=164) HHH ITT analysis: discrepancy (information absent) between
NDA and publication (reported in NDA but not in publication)
19% (24/126)
ITT analysis: discrepancy (information absent) between
NDA and publication (reported in publication but not in
NDA) (only 126 of the 164 NDA trials were published)
18% (23/126)
Soares, 2004 [25] (n=59) ?–H ITT analysis: discrepancy between protocol and publication
(after verification by the Radiation Therapy Oncology Group)
(58 published articles were found for 56 protocols used in
this study, and 48 undertook an ITT analysis)
17% (8/48)
Rosenthal, 2013 [6] (n=51) X–H ITT/PP analysis: discrepancy (information absent) between
registry and publication (reported in publication but not
in registry)
96% (49/51)
Time point outcome was measured: discrepancy between
trial registration and publication
10% (5/51)
Time point outcome was measured: Not pre-specified in
registry but included in publication (information absent)
14% (7/51)
aBased on summary assessments for three domains from Table 4: H = high quality; X =methodological concerns; ? = uncertain quality; – = not applicable.
FDA, US Food and Drug Administration; ITT, intention to treat; NDA, new drug application; PP, per protocol.
doi:10.1371/journal.pmed.1001666.t005
Selective Reporting and Discrepancies in Analyses
PLOS Medicine | www.plosmedicine.org 14 June 2014 | Volume 11 | Issue 6 | e1001666
Results
Search Results
The search strategy identified 600 records. After duplicates were
removed, 446 records were screened, and 390 were excluded. Full
texts were accessed for 56 articles.
The PRISMA flow diagram is shown in Figure 1.
Excluded Studies
Twenty-one articles were excluded after assessment of their full
text: two were reviews; one was not in English; one was reported in
abstract form only and the study was never undertaken; three were
not empirical studies; three included only non-RCTs; and 11 did
not consider analysis-related issues.
Two ongoing studies (four publications) were also identified [7–10].
One study [7,9,10] included 894 protocols (and 520 related journal
publications) approved by six research ethics committees from 2000 to
2003 in Switzerland, Germany, and Canada. The aim of the study
was to determine the agreement between planning of subgroups,
interim analyses, and stopping rules and their reporting in subsequent
publications. A conference abstract was identified in which the
authors assessed RCTs submitted to the European Medicines Agency
for marketing approval and assessed selective reporting of analyses
[8]. The authors were contacted for further details.
Included Studies
Twenty-two studies (in 31 publications) containing a total of
3,140 RCTs were included [6,11–31].
Table 7. Handling missing data.
Study (Maximum
Number of RCTs) Qualitya Results Percent of RCTs (Number)
Chan, 2008 [15] (n=70) H–H Methods of handling missing data: discrepancy between
protocol and publication
80% (39/49)
Methods of handling missing data: discrepancy (information
absent) between publication and protocol (reported in publication
but not in protocol) (the method of handling missing data was
described in 16 protocols and 49 publications)
78% (38/49)
Rising, 2008 [23] (n=164) HHH Method of imputation: discrepancy (information absent) between
NDA and publication (LOCF reported in NDA but not in publication)
8% (10/126)
Method of imputation: discrepancy (information absent) between
NDA and publication (LOCF reported in publication but not in NDA)
9% (11/126)
Method of imputation: discrepancy (information absent) between
NDA and publication (imputation method reported in NDA but not in
publication)
12% (15/126)
Method of imputation: discrepancy (information absent) between
NDA and publication (imputation method reported in publication
but not in NDA) (only 126 of the 164 NDA trials were published)
13% (16/126)
Turner, 2008 [27] (n=74) HHH Methods of handling dropout: discrepancy (contradiction)
between FDA review and publication (only 51 of the 74
FDA-registered studies were published)
12% (6/51)
aBased on summary assessments for three domains from Table 4: H = high quality; – = not applicable.
FDA, US Food and Drug Administration; LOCF, last observation carried forward; NDA, new drug application.
doi:10.1371/journal.pmed.1001666.t007
Table 6. Composite outcomes.
Study (Maximum
Number of RCTs) Qualitya Results Percent of RCTs (Number)
Cordoba,
2010 [16] (n=40)
H–H Composite outcomes: estimates for both the composite
and its components reported in the publication
60% (24/40)
Composite outcomes: discrepancy (contradiction) in
specification between the abstract/methods and results
sections of the publication
33% (13/40)
Composite outcomes: pre-specified composite was
not statistically significant, but the new, post hoc
composite was statistically significant (contradiction)
(four studies constructed a post hoc composite outcome)
75% (3/4)
Composite outcomes: in trials with a statistically
significant composite, the abstract conclusion falsely
implied that the effect applied also to the most important
component (16 trials had a statistically significant
composite outcome)
69% (11/16)
aBased on summary assessments for three domains from Table 4: H = high quality; – = not applicable.
doi:10.1371/journal.pmed.1001666.t006
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All 22 included studies investigated discrepancies, and although
several of these studies considered the statistical significance of
results, none investigated selective reporting bias.
Study Characteristics
Study characteristics are presented in Tables 1–3.
Included cohort studies were published between 2000 and
2013: two compared marketing approval or new drug
applications to publications; one compared US Food and
Drug Administration reviews to publications; one compared
internal company documents to publications; five compared
protocols to publications; two compared trial registry entries
to publications; one compared grant proposals and protocols
to publications; one compared trial registry entries/protocols/
design papers to publications; and nine compared
information within the trial report (i.e., between sections such
as the abstract, methods, and results). Of the cohort studies,
91% (20/22) included only RCTs, with a median of 61 RCTs
per cohort study (interquartile range: 41 to 91; range: 2 to
776).
Included RCTs were published between 1966 and 2012. The
source of funding of RCTs was not considered in 11 of the cohort
studies. In ten studies, industry funded a median of 70.5% of the
RCTs (interquartile range: 46% to 100%). In one study, all of the
RCTs were funded by the Netherlands Organisation for Health
Research and Development.
Methodological Quality
Details of the methodological quality of the included studies are
presented in Table 4.
Independent data extraction by at least two people. We
had methodological concerns about five studies because data
extraction was completed by only one person or only a sample was
checked by a second author. Eleven studies were high quality, as
data extraction was completed by at least two people. Six studies
were rated as uncertain quality, as information regarding data
extraction was not provided.
Definition of positive and negative findings. We had
methodological concerns about one study because positive and
negative findings were not defined, while 11 studies were of high
Table 8. Unadjusted versus adjusted analyses.
Study (Maximum
Number of RCTs) Qualitya Results
Percent of RCTs
(Number)
Chan, 2008 [15] (n=70) H–H Adjusted analyses: discrepancy between protocol and
publication (28 trials described adjusted analyses in the
protocol or publication)
82% (23/28)
Adjusted analyses: discrepancy (information absent)
between protocol and publication (specified in protocol
but the publication reported no adjustment or omitted a
pre-specified covariate) (18 trials described adjusted analyses
in the protocol)
67% (12/18)
Covariates: discrepancy (contradiction) between publication
and protocol (published adjusted analyses in publication using
covariates that were not pre-specified in the protocol or added
a covariate) (18 trials described adjusted analyses in the publication)
67% (12/18)
Yu, 2010 [29] (for 2000:
n=79; for 2006: n=109)
XHH Adjusted analyses (2000): discrepancy between methods
and results sections of the publication
46% (36/79)
Adjusted analyses (2000): discrepancy (contradiction)
between methods and results sections of the publication
(specified adjusted analysis in the methods but reported
only unadjusted results in the results)
6% (2/36)
Adjusted analyses (2000): did not specify clearly the type
of analysis used in the results section
30% (24/79)
Adjusted analyses (2006): did not specify clearly the type
of analysis used in the results section
17% (19/109)
Adjusted analyses (2006): discrepancy (contradiction)
between methods and results sections of the publication
(specified adjusted analysis in the methods but reported
only unadjusted results in the results)
16% (3/19)
Saquib, 2013 [24] (n=199) HHH Adjusted analyses: discrepancy (contradiction) between
trial registry/protocol/design paper and publication (comparisons
were made for 60 published trials for which information on
adjustment was available from the trial registry, protocol, or
design paper)
47% (28/60)
Adjusted analyses: discrepancy (information absent) between
protocol and publication (adjusted analyses not pre-specified in
the protocol but included in the publication)
75% (21/28)
Adjusted analyses: discrepancy (information absent) between
publication and protocol (adjusted analyses pre-specified in the
protocol but not included in the publication)
25% (7/28)
aBased on summary assessments for three domains from Table 4: H = high quality; X =methodological concerns; – = not applicable.
doi:10.1371/journal.pmed.1001666.t008
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quality, with clear definitions of positive and negative findings. Defining
a positive or negative finding was not a study objective in ten studies.
Risk of selective reporting bias in the empirical
study. One study [18] generated methodological concerns
because some secondary analyses were not reported, and the study
report stated only that no difference was observed between positive
and negative trials. The remaining 21 studies were of high quality,
with all comparisons and outcomes stated in the study methods
reported in full. We did not have access to any protocols for the
empirical studies in order to make a more comprehensive assessment
of how each study performed for this methodological quality item.
Statistical Analyses
Eight studies investigated discrepancies in statistical analyses
[6,15,17,20,23,25,27,28]. Table 5 summarises the results of
these studies. Three studies reported discrepancies in the
analysis methods between documents: discrepancy rates ranged
from 7% (3/42) of their included studies to 88% (7/8)
[15,17,27]. Five studies considered whether an intention-to-
treat analysis or per protocol analysis was specified or reported
[6,20,23,25,28]. Three of these studies found discrepancies
between different documents (due to the absence of informa-
tion) in 17% (8/48) to 96% (49/51) of included RCTs [6,23,25],
and another study [28] found discrepancies (due to a contra-
diction) between protocols and publications in 67% (2/3) of
RCTs. Melander et al. found that only one analysis was
reported in 92% (23/25) of RCTs, usually favouring the per
protocol analysis [20]. One study [15] found that an equiva-
lence RCT was reported as a superiority RCT, and that there
were discrepancies (information absent) in interim analyses in
62% (8/13) of RCTs. Rosenthal and Dwan found discrepancies
(contradictions and information absent) between trial registry
entries and publications in the reporting of outcomes at
different time points [6].
Composite Outcomes
One study (Table 6) investigated discrepancies in composite
outcomes [16] and found changes in the specification of the composite
outcome between abstracts, methods, and results sections in 33% (13/
40) of RCTs. In 69% (11/16) of RCTs with a statistically significant
composite outcome, the abstract’s conclusion falsely implied that the
effect was also seen for the most important component. This reporting
strategy of highlighting that the experimental treatment is beneficial
despite a statistically non-significant difference for the primary
outcome is one form of ‘‘spin’’ [32].
Handling Missing Data
Three studies investigated discrepancies in the handling of
missing data [15,23,27] (Table 7). One study found that
methods of handling missing data differed between documents
in 12% (6/51) of RCTs [27]. Chan et al. found discrepancies
in methods between protocols and publications in 80% (39/49)
of RCTs, and also that in 78% (38/49) of RCTs that reported
methods in the publication, these methods were not pre-
specified [15]. Rising et al. [23] found that some studies
reported the method in the new drug application but not in the
trial publication and vice versa.
Unadjusted versus Adjusted Analyses
Three studies [15,24,29] found discrepancies in unadjusted
versus adjusted analyses in 46% (36/79) to 82% (23/28) of RCTs
(Table 8).
Continuous/Binary Data
Two studies investigated discrepancies in the use of continuous
and binary versions of the same underlying data [6,27] (Table 9).
Turner et al. [27] found a continuous measure rendered binary in
1% (1/74) of RCTs, and Rosenthal and Dwan [6] found
discrepancies between trial registry entries and publications in
29% (12/42) of RCTs. A third study, Riveros et al. [31], found that
in 20% (9/45) of RCTs there were discrepancies due to different
types of analysis (i.e., change from baseline versus final-value mean)
between results posted in trial registry entries at ClinicalTrials.gov
and in the corresponding publications. Rosenthal et al. also found
discrepancies (contradictions and information absent) for final
values versus change from baseline [6].
Subgroup Analyses
Twelve studies investigated discrepancies in subgroup analyses
[6,11–15,18,19,21,22,26,30] (Table 10). The majority considered
whether subgroup analyses were pre-specified or post hoc.
Assmann et al. found that it was commonly difficult to
Table 9. Continuous/binary data.
Study (Maximum
Number of RCTs) Qualitya Results Percent of RCTs (Number)
Turner, 2008 [27] (n=74) HHH Measurement scale: continuous measure rendered binary 1% (1/74)
Rosenthal, 2013 [6] (n=51) X–H Cutoffs in binary/categorical variables: discrepancy
between trial registry and publication (12 were not included in
trial registry but included in publication, and only 42 trials
considered cutoffs in binary/categorical variables)
29% (12/42)
Final values versus change from baseline: discrepancy
between trial registry and publication (32 trials included
continuous outcomes measured at baseline and end point)
3% (1/32)
Analysis end point: Not pre-specified in registry but included
in publication (information absent)
41% (13/32)
Riveros, 2013 [31] (n=202) H–H Final values versus change from baseline: discrepancy
between trial registry and publication (107 trials included
continuous outcomes, and comparisons could not be made
for 45 trials)
20% (9/45)
aBased on summary assessments for three domains from Table 4: H = high quality; X =methodological concerns; – = not applicable.
doi:10.1371/journal.pmed.1001666.t009
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Table 10. Subgroup analyses.
Study (Maximum
Number of RCTs) Qualitya Results Percent of RCTs (Number)
Chan, 2008 [15] (n=70) H–H Discrepancy between protocol and publication (25 trials described
subgroup analyses in the protocol or publication)
100% (25/25)
Discrepancy between protocol and publication (pre-specified in
protocol and only some or none reported in publication) (13 trials
described subgroup analyses in the protocol)
92% (12/13)
Discrepancy (information absent) between protocol and
publication (included in the publication, but at least one not
pre-specified in the protocol) (20 trials described subgroup
analyses in the publication)
95% (19/20)
Al-Marzouki, 2008 [11] (n=37) ?–H Publication includes at least one unreported or new subgroup
analysis not mentioned in the protocol (18 trials pre-specified
subgroup analyses in the protocol, 28 trials included subgroup
analyses in the publication)
61% (11/18)
Reason for subgroup selection reported in the protocol 3% (1/37)
Subgroup analyses reported in the publication but not
pre-specified in the protocol (information absent)
58% (11/19)
Reason for these subgroup analyses reported in the publication 0% (0/11)
Sun, 2011 [26] (n=207) HHH Not pre-specified (information absent) (64 trials claimed a
subgroup effect for the primary outcome)
59% (38/64)
At least one subgroup analysis not pre-specified 65% (135/207)
Wang, 2007 [30] (n=59) ?HH Number of subgroup analyses undertaken was unclear 15% (9/59)
Unclear whether any of the subgroup analyses were
pre-specified or post hoc
68% (40/59)
Unclear whether some subgroup analyses were pre-specified 5% (3/59)
Hernandez, 2006 [18] (n=63) HHX Included pre-specified and non-pre-specified subgroups in
the publication
10% (4/39)
Subgroup analyses reported in the publication without a
rationale (39 trials included subgroup analyses in the publication)
54% (21/39)
Bhandari, 2006 [13] (n=72) H–H Subgroup analyses not pre-specified (information absent)
(54 subgroup analyses in 27 trials)
91% (49/54)
Parker, 2000 [22] (n=67) ?HH Subgroup analyses post hoc 14% (8/58)
partially pre-specified and partially post hoc 10% (6/58)
Subgroup analyses failed to indicate whether they were
pre-specified or not (58 trials reported subgroup analyses)
35% (20/58)
Hernandez, 2005 [19] (n=18) XXH Pre-specified subgroups not reported in the publication
(information absent)
27% (3/11)
Partially pre-specified subgroups were reported in the
publication (11 trials reported subgroup analyses)
46% (5/11)
Discrepancy (information absent) between protocol and
publication (subgroup analyses not pre-specified in the
protocol but reported in publication)
50% (3/6)
Discrepancy between publication and protocol (subgroup
analyses pre-specified in the protocol but not reported in
publication as planned) (protocols were available for six trials)
33% (2/6)
Moreira, 2001 [21] (n=32) X–H Subgroup analyses unclear 6% (1/17)
Subgroup analyses omitted from the publication
(information absent) (17 trials had at least one
subgroup analysis)
53% (9/17)
Subgroups defined after randomisation (14 trials reported
when subgroups were defined in the publication)
82% (4/14)
Boonacker, 2011 [14] (n=79) ?HH Discrepancy between the grant proposal and publication
(47 were RCTs only)
77% (36/47)
Discrepancy between the grant proposal and publication 75% (59/79)
Discrepancy in pre-specified subgroup analyses between
the grant proposal and publication
90% (44/49)
Discrepancy (information absent) in pre-specified subgroup
analyses between the grant proposal and publication
(pre-specified subgroups not reported)
22% (11/49)
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distinguish between these different timings for the choice of
subgroup analyses [12]. Four studies considered discrepancies;
and the discrepancy rate ranged from 61% (11/18) to 100%
(25/25) of RCTs in three studies [11,14,15]. The fourth study
found subgroup analyses reported in only seven RCTs, and no
details had been included in the trial registry entries for six of
these RCTs, while the seventh had no discrepancies [6]. In
seven studies [11,13,18,21,22,26,30], where the comparison
was mostly made between the methods and results sections of
the trial publication, it was found that a number of subgroup
analyses conducted were not pre-specified (range: 14% [8/58]
to 91% [49/54] of RCTs), pre-specified, but not reported in
the publication (range: 27% [3/11] to 53% [9/17]), or
contained a mixture of pre-specified and non-pre-specified
subgroup analyses (range: 10% [6/58] to 65% [135/207]).
Funding
Although 11 studies looked at funding as a study character-
istic, only two considered the relationship between discrepan-
cies and funding. Sun et al. found that trials funded by industry
were more likely to report subgroup results when the primary
outcome was not statistically significant compared to when the
primary outcome was statistically significant (odds ratio 3.00
[95% CI: 1.56 to 5.76], p= 0.001) [26].
Rosenthal and Dwan found no statistically significant differ-
ences in discrepancy rates of primary and secondary outcomes
between registry entries and final reports of industry-sponsored
versus non–industry-sponsored trials [6].
Discussion
Summary of Main Results
Twenty-two cohort studies of RCTs were included in this
review that examined discrepancies between information given in
different sources. Many different types of discrepancies in
analyses between documents were found, and discrepancy rates
ranged from 7% (3/42) to 88% (7/8) for analysis methods, 46%
(36/79) to 82% (23/28) for the presentation of adjusted versus
unadjusted analyses, and 61% (11/18) to 100% (25/25) for
subgroup analyses.
None of the included studies examined the selective reporting bias
of analyses in RCTs that would arise if analyses were reported or
concealed because of the results. Such an assessment may prove to be
difficult without access to statistical analysis plans and trial datasets to
determine the statistical significance of the results for the analyses that
were planned and for those that were reported.
The majority of studies (12) focussed on the reporting of
subgroup analyses. None of the included studies provided any
detail on the reasons for inconsistencies. A number of studies
commented on whether or not reported subgroup analyses
were pre-specified. While this may not be seen as a
comparison, we reported the findings for these studies within
this review because post hoc decisions about which subgroups
to analyse and report may be influenced by the findings of
those or related analyses. There are likely to be many other
selective inclusion and reporting mechanisms for which there is
no current empirical evidence, and a more complete categor-
isation is provided elsewhere [4]. The methodological concerns
that were observed in the included studies were not critical,
and they should not impact importantly on the interpretation
of the results of the studies.
These discrepancies may be due to reporting bias, errors, or
legitimate departures from a pre-specified protocol. Reliance on
the source documentation to distinguish between these reasons
may be inadequate, and contact with trial authors may be
necessary. Only one study [29] contacted the original authors of
the RCTs for information about the discrepancies, but only 9%
(3/34) of those authors replied, and no details were given on the
reasons for the discrepancies. In terms of selective reporting of
outcomes, a previous study interviewed a cohort of trialists about
outcomes that were specified in trial protocols but not fully
reported in subsequent publications [33]. In nearly a quarter of
trials (24%, 4/17) in which pre-specified outcomes had been
measured but not analysed, the ‘‘direction’’ of the main findings
influenced the investigators’ decision not to analyse the remaining
data collected.
Table 10. Cont.
Study (Maximum
Number of RCTs) Qualitya Results Percent of RCTs (Number)
Discrepancy in pre-specified subgroup analyses between
the grant proposal and publication (added/omitted subgroups
from publications) (49 studies mentioned subgroups in their grant
application)
67% (33/49)
Subgroups included in the publication (30 did not pre-specify
subgroups)
50% (15/30)
No discrepancy between protocol and grant proposal 62% (13/21)
No discrepancy between protocol and publication (a protocol
was available for 21 trials)
38% (8/21)
Subgroup effects were reported only for significant interaction
tests (four publications included interaction tests)
75% (3/4)
Rosenthal, 2013 [6] (n=51) X–H Discrepancy between trial registry and publication 0% (0/7)
Subgroup analyses not included in trial registry but included in
publication (information absent) (seven trials included subgroup
analyses in trial registry or publication)
86% (6/7)
Assmann, 2000 [12] (n =50) H–H It was commonly difficult to determine whether subgroup
analyses were pre-defined or post hoc
Not applicable
aBased on summary assessments for three domains from Table 4: H = high quality; X =methodological concerns; ? = uncertain quality; – = not applicable.
doi:10.1371/journal.pmed.1001666.t010
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Agreements and Disagreements with Other Studies or
Reviews
Three of the included studies [11,17,25] were included in a
previous Cochrane methodology review that was restricted to
studies that compared any aspect of trial protocols or trial registry
entries to publications [5]. The conclusions of the current review
and the previous review are similar in that discrepancies were
common, and reasons for them were rarely reported in the original
RCTs. This current review focussed on analyses only, and
included studies that compared different pieces of trial documen-
tation or details within a trial publication.
Implications for RCTs
In accordance to International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
Human Use E 9 guidance (Statistical Principles for Clinical Trials [34]),
procedures for executing the statistical analysis of the primary,
secondary, and other data should be finalised before breaking the
blind on those analyses. The availability of a trial protocol (or separate
statistical analysis plan) is of prime importance for inferring whether
the results presented are a selected subset of the analyses that were
actually done and whether there are legitimate reasons for departures
from a pre-specified protocol. Many leading medical journals, e.g.,
PLOS Medicine (http://www.plosmedicine.org/static/guidelines.
action) and the British Medical Journal (http://www.bmj.com/about-
bmj/resources-authors/article-submission/article-requirements), now
require the submission of a trial protocol alongside the report of the
RCT for comparison during the peer review process. In order to
ensure transparency, protocols and any separate analysis plans for all
trials need to be made publicly available, along with the date that the
statistical analysis plan was finalised, details of reasons for any changes,
and the dates of those changes. Additional analyses suggested by peer
reviewers when a manuscript is submitted for publication should be
judged on their own merits, and any additional analyses that are
included in the final paper should be labelled as such.
Whilst evidence-based guidelines exist for researchers to develop
high-quality protocols for clinical trials (e.g., SPIRIT [35]) and for
reporting trial findings (CONSORT [36]), more guidance is
needed for writing statistical analysis plans.
Implications for Systematic Reviews and Evaluations of
Healthcare
Systematic reviewers need to ensure they access all possible trial
documentation, whether it is publicly available or obtained from
the trialists, in order to assess the potential for selective reporting
bias for analyses. The Cochrane risk of bias tool is currently being
updated, and the revised version will acknowledge the possibility of
selective analysis reporting in addition to selective outcome
reporting. Selective analysis reporting generally leads to a reported
result that may be biased, so sits more naturally alongside other
aspects of bias assessment of trials, such as randomisation methods,
use of blinding, and patient exclusions. Selective outcome
reporting may lead either to bias in a reported result (e.g., if a
particular measurement scale is selected from among several) or to
non-availability of any data for a particular outcome (e.g., if no
measures for an outcome are reported). The latter sits more
naturally alongside consideration of ‘‘publication bias’’ (suppres-
sion of all information about a trial).
Conclusions
There are to date no readily accessible data on selective reporting
bias of analyses in cohorts of RCTs. Studies that have compared
source documentation from before the start of a trial with the final
trial publication have found a number of discrepancies in the way
that analyses were planned and conducted. From the published
literature, there is insufficient information to distinguish between
bias, error, and legitimate changes. Reliance on the source
documentation to distinguish between these may be inadequate,
and contact with trial authors may be necessary. If journals insisted
that authors provide protocols and analysis plans, selective reporting
would be more easily detectable, and possibly reduced. Journals
could flag research articles that provide no protocol or statistical
analysis plans. More guidance is needed on how a detailed statistical
analysis plan should be written.
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Editors’ Summary
Background. In the past, clinicians relied on their own
experience when choosing the best treatment for their
patients. Nowadays, they turn to evidence-based medicine—
the systematic review and appraisal of trials, studies that
investigate the benefits and harms of medical treatments in
patients. However, evidence-based medicine can guide
clinicians only if all the results from clinical trials are
published in an unbiased and timely manner. Unfortunately,
the results of trials in which a new drug performs better than
existing drugs are more likely to be published than those in
which the new drug performs badly or has unwanted side
effects (publication bias). Moreover, trial outcomes that
support the use of a new treatment are more likely to be
published than those that do not support its use (outcome
reporting bias). Recent initiatives—such as making registra-
tion of clinical trials in a trial registry (for example,
ClinicalTrials.gov) a prerequisite for publication in medical
journals—aim to prevent these biases, which pose a threat
to informed medical decision-making.
Why Was This Study Done? Selective reporting of
analyses of outcomes may also affect the validity of
clinical trial findings. Sometimes, for example, a trial
publication will include a per protocol analysis (which
considers only the outcomes of patients who received
their assigned treatment) rather than a pre-planned
intention-to-treat analysis (which considers the outcomes
of all the patients regardless of whether they received
their assigned treatment). If the decision to publish the
per protocol analysis is based on the results of this
analysis being more favorable than those of the inten-
tion-to-treat analysis (which more closely resembles
‘‘real’’ life), then ‘‘analysis reporting bias’’ has occurred.
In this systematic review, the researchers investigate the
selective reporting of analyses and discrepancies in
randomized controlled trials (RCTs) by reviewing pub-
lished studies that assessed selective reporting of anal-
yses in groups (cohorts) of RCTs and discrepancies in
analyses of RCTs between different sources (for example,
between the protocol in a trial registry and the journal
publication) or different sections of a source. A systematic
review uses predefined criteria to identify all the research
on a given topic.
What Did the Researchers Do and Find? The researchers
identified 22 cohort studies (containing 3,140 RCTs) that
were eligible for inclusion in their systematic review. All of
these studies reported on discrepancies between the
information provided by the RCTs in different places, but
none investigated the evidence for analysis reporting bias.
Several of the cohort studies reported, for example, that
there were discrepancies in the statistical analyses included
in the different documents associated with the RCTs
included in their analysis. Other types of discrepancies
reported by the cohort studies included discrepancies in the
reporting of composite outcomes (an outcome in which
multiple end points are combined) and in the reporting of
subgroup analyses (investigations of outcomes in subgroups
of patients that should be predefined in the trial protocol
to avoid bias). Discrepancy rates varied among the RCTs
according to the types of analyses and cohort studies
considered. Thus, whereas in one cohort study discrepancies
were present in the statistical test used for the analysis of the
primary outcome in only 7% of the included studies, they
were present in the subgroup analyses of all the included
studies.
What Do These Findings Mean? These findings indicate
that discrepancies in analyses between publications and
other study documents such as protocols in trial registries
are common. The reasons for these discrepancies in
analyses were not discussed in trial reports but may be
the result of reporting bias, errors, or legitimate depar-
tures from a pre-specified protocol. For example, a
statistical analysis that is not specified in the trial protocol
may sometimes appear in a publication because the
journal requested its inclusion as a condition of publica-
tion. The researchers suggest that it may be impossible
for systematic reviewers to distinguish between these
possibilities simply by looking at the source documenta-
tion. Instead, they suggest, it may be necessary for
reviewers to contact the trial authors. However, to make
selective reporting of analyses more easily detectable,
they suggest that protocols and analysis plans should be
published and that investigators should be required to
stick to these plans or explain any discrepancies when
they publish their trial results. Together with other
initiatives, this approach should help improve the quality
of evidence-based medicine and, as a result, the treat-
ment of patients.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001666.
N Wikipedia has pages on evidence-based medicine, on
systematic reviews, and on publication bias (note: Wikipe-
dia is a free online encyclopedia that anyone can edit;
available in several languages)
N ClinicalTrials.gov provides information about the US
National Institutes of Health clinical trial registry, including
background information about clinical trials
N The Cochrane Collaboration is a global independent
network of health practitioners, researchers, patient
advocates, and others that aims to promote evidence-
informed health decision-making by producing high-
quality, relevant, accessible systematic reviews
and other synthesized research evidence; the
Cochrane Handbook for Systematic Reviews of
Interventions describes the preparation of systematic
reviews in detail
N PLOS Medicine recently launched a Reporting Guidelines
Collection, an open-access collection of reporting guide-
lines, commentary, and related research on guidelines
from across PLOS journals that aims to help advance the
efficiency, effectiveness, and equitability of the dissemina-
tion of biomedical information
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